Results 101 to 110 of about 13,526 (188)

Nintedanib Treatment After Ovulation is an Effective Therapeutic Strategy for the Alleviation of Ovarian Hyperstimulation Syndrome (OHSS) in a Mouse Model

Drug Design, Development and Therapy, 2022
Shutian Jiang,* Wenzhi Li,* Xinxi Zhao, Li Chen, Yanping Kuang Department of Assisted Reproduction, Shanghai Ninth People’s Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People’s Republic of China*These authors ...
Jiang S, Li W, Zhao X, Chen L, Kuang Y
doaj  

Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis [PDF]

, 2018
Background: Nintedanib is a tyrosine kinase inhibitor that has recently been shown to slow disease progression in idiopathic pulmonary fibrosis in two replicate phase III clinical trials.
Distler, Alfiya, Wollin, Lutz, Distler, Jörg H. W., Zhang, Yun, Gelse, Kolja, Beyer, Christian, Ramming, Andreas, Schett, Georg, Huang, Jingang, Distler, Oliver, Palumbo-Zerr, Katrin   +10 more
core   +1 more source

Patient characteristics and pharmacologic treatment patterns in antifibrotic-treated patients with fibrosing interstitial lung diseases: real-world results from a claims database

BMC Pulmonary Medicine
Background Antifibrotics have been approved for use in many countries, including Japan, based on the results of several phase III clinical trials in patients with IPF, SSc-ILD, and PPF, which showed slower lung function decline with antifibrotic ...
Yasuhiro Kondoh, Tomohiro Ito, Hana Kimura, Haikun Bao, Masataka Kuwana   +4 more
doaj   +1 more source

Acute thrombocytopenia and fibrinogen reduction occurring after nintedanib treatment for immune checkpoint inhibitor-related pneumonia: a case report

Frontiers in Oncology
BackgroundNintedanib, a small molecule multi-target tyrosine kinase inhibitor, can block the fibrosis process and slow disease progression. Acute thrombocytopenia and fibrinogen reduction caused by nintedanib is a rare clinical event, with few studies ...
Jian Zheng, Nan Zhou, Dexiang Pang
doaj   +1 more source

Continued Treatment with Nintedanib in Patients with Progressive Pulmonary Fibrosis: Data from INBUILD-ON [PDF]

PurposeIn the INBUILD trial in patients with progressive pulmonary fibrosis (PPF), nintedanib slowed the decline in forced vital capacity (FVC) versus placebo, with a safety profile characterised mainly by gastrointestinal events.
Dumistracel, Mihaela, Wuyts, Wim A, Varone, Francesco, Miede, Corinna, Coeck, Carl, Bonella, Francesco, Cottin, Vincent, Antin-Ozerkis, Danielle, Chaudhuri, Nazia, Song, Jin Woo   +9 more
core   +1 more source

Nintedanib alleviates hyperoxia-induced lung injury via targeting NF-κB signalling pathway in rat model of bronchopulmonary dysplasia

Folia Histochemica et Cytobiologica
INTRODUCTION: Bronchopulmonary dysplasia (BPD) is a common chronic respiratory disease in premature infants. Hyperoxia is the main pathogenic factor of BPD.
Rui Hao, Yuping Li, Junhui Li, Zirui Guo, Zhi Yang, Wei Lu   +5 more
doaj   +1 more source

Reduced tracheal stenosing effect of nintedanib in a patient with scarred posttraumatic tracheal stenosis and airflow limitation - a case report

Respiratory Medicine Case Reports
Introduction: Nintedanib is a tyrosine kinase inhibitor and has been approved for the treatment of idiopathic pulmonary fibrosis (IPF) since 2020. In Clinical trials, the antifibrotic effect of nintedanib was shown.
Stefanie Klampfleitner, Andreas Fertl, Ositha Prinz, Martin Doerfler-Schalm, Dieter Munker, Markus O. Henke   +5 more
doaj   +1 more source

Nintedanib for treating idiopathic pulmonary fibrosis

, 2015
To appraise the clinical and cost effectiveness of nintedanib within its licensed indication for treating idiopathic pulmonary ...
Streit, Elke, Rose, Micah, Kalita, Neelam, Cooper, Keith, Pickett, Karen, Shepherd, Jonathan, Picot, Joanna   +6 more
core   +1 more source

Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib

Biologics: Targets & Therapy, 2015
Martin Reck,1 Anders Mellemgaard2 1Department of Thoracic Oncology, Lung Clinic Grosshansdorf, and member of the Airway Research Center North, German Center for Lung Research, Grosshansdorf, Germany; 2Department of Oncology, Herlev University Hospital ...
Reck M, Mellemgaard A
doaj  

A Comparative Assessment of the Antifibrotic Effect of Nintedanib Administered via a Medicated Diet or Oral Gavage in a Rat Model of Bleomycin-Induced Pulmonary Fibrosis. [PDF]

Int J Mol Sci
Pitozzi V, Caruso P, Pontis S, Ruscitti F, Pittelli MG, Aquino G, Volta R, Pappani A, Barrea M, Quaini F, Lagrasta CAM, Nogara AM, Spagnolo P, Trevisani M.   +13 more
europepmc   +1 more source